Patents for A61P 35 - Antineoplastic agents (221,099)
08/2007
08/23/2007US20070197514 Conjugates with organic acids; uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents; the organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity
08/23/2007US20070197510 Nitriles and medicinal compositions containing the same as the active ingredient
08/23/2007US20070197499 Pharmaceutical compounds
08/23/2007US20070197493 Selenophene anti-tumor agents
08/23/2007US20070197462 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus (EBV) or Kaposi's sarcoma-associated herpes (KHSV)
08/23/2007US20070197428 Novel indications of mannan-binding lectin (MBL) in the treatment of immuno-compromised individuals
08/23/2007US20070197424 Glatiramer acetate for use as an immuno-modulatory agent
08/23/2007US20070196445 Method for the Prevention and Treatment of Cachexia and Anorexia
08/23/2007US20070196391 Mucosal boosting following parenteral priming
08/23/2007US20070196377 polynucleotide; rho genes rho proteins; guanosine triphosphate binding proteins; antibody against the protein encodes polynucleotide; detection and treating stomach tumor; determining a disease, a pharmaceutical composition, and a reagent kit
08/23/2007US20070196370 Type 2 cytokine receptor and nucleic acids encoding same
08/23/2007US20070196369 MHC-peptide complex binding ligands
08/23/2007US20070196346 Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer
08/23/2007US20070196339 Modified hpv e6 and e7 genes and proteins useful for vaccination
08/23/2007US20070196336 Method For Constructing Recombinant Herpes Simplex Virus
08/23/2007US20070196332 Cytotoxic agents comprising taxanes and their therapeutic use
08/23/2007US20070196331 Methods and compositions for mobilizing stem cells
08/23/2007US20070196276 Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
08/23/2007DE20023910U1 Pharmakologisch wirksame Substanz zur Behandlung kardiovasulärer Erkrankungen Pharmacologically active substance for treating diseases kardiovasulärer
08/23/2007DE102006008074A1 Behandlung von Krebs mit Geruchsrezeptor-Liganden Treatment of cancer with olfactory receptor ligands
08/23/2007DE102006007433A1 Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure Adjuvant in the form of a lipid-modified nucleic acid
08/23/2007CA2642847A1 Dissolution aids for oral peptide delivery comprising a biguanide
08/23/2007CA2642738A1 Pi-3 kinase inhibitors and methods of their use
08/23/2007CA2642606A1 Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
08/23/2007CA2641933A1 Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
08/23/2007CA2641776A1 Pyrazoloquinolones are potent parp inhibitors
08/23/2007CA2641384A1 Ibandronate regimen for treating metastatic bone pain
08/23/2007CA2641254A1 Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
08/23/2007CA2640509A1 Use of gallium(iii) complexes for the treatment of melanomas
08/23/2007CA2640286A1 Use of local immune suppression to enhance oncolytic viral therapy
08/23/2007CA2618628A1 Triazole compounds that modulate hsp90 activity
08/22/2007EP1820861A2 C3B/C4B complement receptor-like molecules and uses thereof
08/22/2007EP1820859A2 Methods and compositions for inhibiting neoplastic cell growth
08/22/2007EP1820805A2 Inhibitor and stimulator of haemotopoietic stem cell proliferation and uses thereof
08/22/2007EP1820514A2 Therapeutic compositions that produce an immune response by altering the antigen
08/22/2007EP1820513A1 Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
08/22/2007EP1820503A2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
08/22/2007EP1820500A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor
08/22/2007EP1820495A2 Microspheres for active embolization
08/22/2007EP1820442A1 Noninvasive measurements of chemical substances
08/22/2007EP1819728A2 Il-7 variants with reduced immunogenicity
08/22/2007EP1819721A1 Microcin b17 analogs and methods for their preparation and use
08/22/2007EP1819708A2 Substituted pteridines for treating inflammatory diseases
08/22/2007EP1819697A1 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
08/22/2007EP1819696A1 Polymorphic forms of 6-2-(methylcarbamoyl)phenysulfanyl|-3-e-2-(pyridin-2-yl)ethenyl indazole
08/22/2007EP1819688A2 Crystalline forms of docetaxel and processes for their preparation
08/22/2007EP1819679A2 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
08/22/2007EP1819669A2 Novel inhibitors of histone deacetylase for the treatment of disease
08/22/2007EP1819359A2 Anti-integrin immunoconjugates, methods and uses
08/22/2007EP1819339A1 A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-`1,3,4-oxadiazol-2-ylüphenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer
08/22/2007EP1819331A1 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
08/22/2007EP1819227A1 Pharmaceutical formulation of decitabine
08/22/2007EP1734972A4 Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs
08/22/2007EP1592431A4 Method of modulating il-6
08/22/2007EP1499320B1 Novel compounds
08/22/2007EP1490405B1 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
08/22/2007EP1448523B1 Heterocyclic compounds and methods of use
08/22/2007EP1406998B1 Liver engrafting cells, assays, and uses thereof
08/22/2007EP1399433B1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
08/22/2007EP1326961B1 Compositions and methods for inducing specific cytolytic t cell responses
08/22/2007EP1227813B1 REVERSE-TURN MIMETICS AS alpha 4ß INTEGRIN INHIBITORS
08/22/2007EP1190040B1 Herpes simplex virus expressing interleukin-12 gene and and its use for treating cancer
08/22/2007EP1183256B1 Purine derivatives, preparation method and pharmaceutical compositions containing same
08/22/2007EP1178952B1 Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
08/22/2007EP1157040B1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
08/22/2007EP1150980B1 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
08/22/2007EP1124824B1 Chromenone and chromanone derivatives as integrin inhibitors
08/22/2007EP1124568B1 Polyspecific binding molecules and uses thereof
08/22/2007EP0925069B1 Use of cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer
08/22/2007EP0773950B1 Linked peptide nucleic acids
08/22/2007CN1332978C Peptide as antagonist of VEGF receptor Flt-1
08/22/2007CN1332974C Nevol anti-estrogenic steroids, and associated pharmaceutical compositions and method of use
08/22/2007CN1332961C Inhibitors of alpha L beta 2 mediated cell adhesion
08/22/2007CN1332960C Imidazoquinoline derivatives as adenosine A3 receptor ligands
08/22/2007CN1332939C Novel compounds inhibiting factor Xa activity
08/22/2007CN1332716C High molecular antineoplastic cisplatin medicine and preparation method thereof
08/22/2007CN1332713C Methods for inhibiting brain tumor growth
08/22/2007CN1332712C Oncolytic virus therapy
08/22/2007CN1332706C Chinese medicine for treating liver diseases
08/22/2007CN1332705C Chinese medicine for treating liver diseases
08/22/2007CN1332687C Fatty acid synthetic enzyme inhibitor and its production method and application
08/22/2007CN1332678C Tumour control pill
08/22/2007CN1332672C Arsenic trioxide powder for injection
08/22/2007CN1332668C Cepharanthine slow releasing preparation
08/22/2007CN101023164A Cancerous disease modifying antibodies
08/22/2007CN101023090A Prodrugs of HIV protease inhibitors
08/22/2007CN101023086A Selected fused heterocyclics and uses thereof
08/22/2007CN101023082A Fused pyrimidones useful in the treatment and the prevention of cancer
08/22/2007CN101023080A Thiazolinone 4-monosubstituted quinolines
08/22/2007CN101023079A Substituted hydantoins for the treatment of cancer
08/22/2007CN101023074A Inhibitors of the interaction between MDM2 and P53
08/22/2007CN101023072A Piperidinyl targeting compounds that selectively bind integrins
08/22/2007CN101022853A Mixture of catechins or polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (BPH)
08/22/2007CN101022826A Bacterial compositions for the treatment of cancer
08/22/2007CN101022809A Dihydropteridinones for the treatment of cancer diseases
08/22/2007CN101022805A Process to prepare camptothecin derivatives
08/22/2007CN101022790A Acid containing oxaliplatin formulations
08/22/2007CN101020913A Sesquiterpene from marine microbe and possessing powerful antitumor activity
08/22/2007CN101020719A Composite angelica polysaccharide and its prepn process and use
08/22/2007CN101020716A Prepn and application of human tumor relevant N-jointing glycosyl chain monoclonal antibody